Agile Therapeutics (AGXRW) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 10, 2022
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-36464
Entity Registrant Name	AGILE THERAPEUTICS INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-2936302
Entity Address, Address Line One	500 College Road East, Suite 300
Entity Address, City or Town	Princeton
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08540
City Area Code	609
Local Phone Number	683-1880
Title of 12(b) Security	Common stock
Trading Symbol	AGRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		39,023,023
Entity Central Index Key	0001261249
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 13,027	$ 19,143
Accounts receivable, net	2,087	1,533
Inventory, net	2,340	966
Prepaid expenses and other current assets	1,016	2,283
Total current assets	18,470	23,925
Property and equipment, net	11,524	12,447
Right of use asset	825	949
Other non-current assets	2,012	2,012
Total assets	32,831	39,333
Current liabilities:
Long-term debt, current portion	12,630	16,833
Accounts payable	12,036	8,707
Accrued expenses	3,877	3,563
Lease liability, current portion	239	175
Total current liabilities	28,782	29,278
Lease liabilities, long-term	630	784
Total liabilities	29,412	30,062
Commitments and contingencies (Note 10)
Stockholders' equity
Common stock, $.0001 par value, 300,000,000 shares authorized, 12,360,157 and 3,034,901 issued and outstanding at June 30, 2022 and December 31, 2021, respectively	1
Additional paid-in capital	414,523	396,388
Accumulated deficit	(411,105)	(387,117)
Total stockholders' equity	3,419	9,271
Total liabilities and stockholders' equity	$ 32,831	$ 39,333

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Apr. 26, 2022	Apr. 25, 2022	Dec. 31, 2021
Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Preferred stock, authorized (in shares)	10,000,000			10,000,000
Preferred stock, issued (in shares)	4,850			0
Preferred stock, outstanding (in shares)	0			0
Common stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Common stock, authorized (in shares)	300,000,000			300,000,000
Common stock, issued (in shares)	12,360,157			3,034,901
Common stock, outstanding (in shares)	12,360,157	3,668,546	146,741,862	3,034,901

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statements of Operations
Revenues, net	$ 2,126	$ 1,185	$ 3,887	$ 1,301
Cost of product revenues	2,231	1,145	3,758	2,306
Gross profit (loss)	(105)	40	129	(1,005)
Operating expenses:
Research and development	856	862	2,113	2,975
Selling and marketing	7,411	11,977	17,964	21,240
General and administrative	3,026	3,852	7,023	7,653
Total operating expenses	11,293	16,691	27,100	31,868
Loss from operations	(11,398)	(16,651)	(26,971)	(32,873)
Other income (expense)
Interest income	2	7	3	23
Interest expense	(823)	(993)	(1,695)	(1,915)
Total other income (expense), net	(821)	(986)	(1,692)	(1,892)
Loss before benefit from income taxes	(12,219)	(17,637)	(28,663)	(34,765)
Benefit from income taxes			4,675
Net loss	$ (12,219)	$ (17,637)	$ (23,988)	$ (34,765)
Net loss per share (basic) (in dollars per share)	$ (2.71)	$ (8)	$ (6.29)	$ (15.60)
Net loss per share (diluted) (in dollars per share)	$ (2.71)	$ (8)	$ (6.29)	$ (15.60)
Weighted-average common shares (basic) (in shares)	4,510,219	2,217,349	3,816,569	2,204,073
Weighted-average common shares (diluted) (in shares)	4,510,219	2,217,349	3,816,569	2,204,073
Comprehensive loss:
Net loss	$ (12,219)	$ (17,637)	$ (23,988)	$ (34,765)
Other comprehensive income:
Unrealized loss on marketable securities				(3)
Comprehensive loss	$ (12,219)	$ (17,637)	$ (23,988)	$ (34,768)

Statements of Changes in Stockh

Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock Series A Convertible Preferred Stock	Preferred Stock Series B Convertible Preferred Stock	Preferred Stock Series A and B Convertible Preferred Stock	Preferred Stock	Common stock At-the-market sales	Common stock Series A Convertible Preferred Stock	Common stock Series B Convertible Preferred Stock	Common stock	Additional Paid in Capital. At-the-market sales	Additional Paid in Capital. Series A Convertible Preferred Stock	Additional Paid in Capital. Series B Convertible Preferred Stock	Additional Paid in Capital.	Accumulated Other Comprehensive Income	Accumulated Deficit	At-the-market sales	Series A and B Convertible Preferred Stock	Total
Balance at Dec. 31, 2020												$ 361,548	$ 3	$ (312,223)			$ 49,328
Balance (in shares) at Dec. 31, 2020								2,189,094
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												742					742
Issuance of common stock									$ 960						$ 960
Issuance of common stock (in shares)					13,023
Issuance of common stock upon exercise of options												75					75
Issuance of common stock upon exercise of options (in shares)								3,160
Vesting of RSUs (in shares)								1,316
Warrants issued in connection with long-term debt												1,080					1,080
Unrealized net gain on marketable securities													(3)				(3)
Net loss														(17,128)			(17,128)
Balance at Mar. 31, 2021												364,405		(329,351)			35,054
Balance (in shares) at Mar. 31, 2021								2,206,593
Balance at Dec. 31, 2020												361,548	$ 3	(312,223)			49,328
Balance (in shares) at Dec. 31, 2020								2,189,094
Increase (decrease) in stockholders' equity
Unrealized net gain on marketable securities																	(3)
Net loss																	(34,765)
Balance at Jun. 30, 2021												371,597		(346,988)			24,609
Balance (in shares) at Jun. 30, 2021								2,323,205
Balance at Mar. 31, 2021												364,405		(329,351)			35,054
Balance (in shares) at Mar. 31, 2021								2,206,593
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												843					843
Issuance of common stock									6,349						6,349
Issuance of common stock (in shares)					114,826
Vesting of RSUs (in shares)								1,786
Net loss														(17,637)			(17,637)
Balance at Jun. 30, 2021												371,597		(346,988)			24,609
Balance (in shares) at Jun. 30, 2021								2,323,205
Balance at Dec. 31, 2021												396,388		(387,117)			9,271
Balance (in shares) at Dec. 31, 2021								3,034,901
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												764					764
Issuance of common stock									348						348
Issuance of common stock (in shares)					25,623
Registered direct financing costs, inclusive of warrants				$ (965)								244					(721)
Conversion of convertible preferred stock	$ (897)		$ 4,850							$ 897						$ 4,850
Conversion of convertible preferred stock (in shares)	(2,425)		4,850			303,125
Vesting of RSUs (in shares)								1,773
Warrants issued in connection with registered direct offering				(2,101)								2,101
Net loss														(11,769)			(11,769)
Balance at Mar. 31, 2022				$ 887								400,742		(398,886)			2,743
Balance (in shares) at Mar. 31, 2022				2,425				3,365,422
Balance at Dec. 31, 2021												396,388		(387,117)			9,271
Balance (in shares) at Dec. 31, 2021								3,034,901
Increase (decrease) in stockholders' equity
Net loss																	(23,988)
Balance at Jun. 30, 2022								$ 1				414,523		(411,105)			3,419
Balance (in shares) at Jun. 30, 2022								12,360,157
Balance at Mar. 31, 2022				$ 887								400,742		(398,886)			2,743
Balance (in shares) at Mar. 31, 2022				2,425				3,365,422
Increase (decrease) in stockholders' equity
Share-based compensation - stock options and RSUs												669					669
Fractional shares retired as a result of reverse split								(10)
Issuance of common stock					$ 1				$ 12,225						$ 12,226
Issuance of common stock (in shares)					8,687,502
Conversion of convertible preferred stock		$ (887)									$ 887
Conversion of convertible preferred stock (in shares)		(2,425)					303,125
Vesting of RSUs (in shares)								4,118
Net loss														(12,219)			(12,219)
Balance at Jun. 30, 2022								$ 1				$ 414,523		$ (411,105)			$ 3,419
Balance (in shares) at Jun. 30, 2022								12,360,157

Statements of Changes in Stoc_2

Statements of Changes in Stockholders' Equity (Parenthetical)	Apr. 26, 2022
Statements of Changes in Stockholders' Equity
Stockholders' Equity Note, Stock Split, Conversion Ratio	0.025

Statements of Cash Flows

Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (23,988,000)	$ (34,765,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,057,000	1,029,000
Amortization	124,000	67,000
Noncash stock-based compensation	1,433,000	1,585,000
Noncash interest	797,000	864,000
Changes in operating assets and liabilities:
Accounts receivable	(554,000)	(302,000)
Inventory	(1,374,000)	(3,462,000)
Prepaid expenses and other assets	1,267,000	552,000
Accounts payable and accrued expenses	3,643,000	4,494,000
Lease liability	(90,000)	(66,000)
Net cash used in operating activities	(17,685,000)	(30,004,000)
Cash flows from investing activities:
Sales and maturities of marketable securities		34,729,000
Acquisition of property and equipment	(133,000)	(149,000)
Net cash (used in) provided by investing activities	(133,000)	34,580,000
Cash flows from financing activities:
Repayments of long-term debt	(5,000,000)
Proceeds from exercise of stock options		75,000
Net cash provided by financing activities	11,702,000	7,079,000
Net (decrease) increase in cash and cash equivalents	(6,116,000)	11,655,000
Cash and cash equivalents, beginning of period	19,143,000	14,463,000
Cash and cash equivalents, end of period	13,027,000	26,118,000
Supplemental disclosure of noncash financing activities
Warrants issued in connection with long-term debt		1,080,000
Warrants issued in connection with preferred stock offering	2,101,000
Supplemental cash flow information
Interest paid	898,000	1,182,000
Series A Convertible Preferred Stock
Supplemental disclosure of noncash financing activities
Conversion of Series preferred stock into common stock	897,000
Series B Convertible Preferred Stock
Supplemental disclosure of noncash financing activities
Conversion of Series preferred stock into common stock	887,000
Public offering
Cash flows from financing activities:
Proceeds from issuance of preferred stock in registered direct offering, net of offering costs	4,129,000
At-the-market sales
Cash flows from financing activities:
Proceeds from At-the-Market sales of common stock, net of offering costs	$ 12,573,000	$ 7,004,000

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2022
Organization and Description of Business
Organization and Description of Business	Nature of Operations Agile Therapeutics, Inc. (“Agile” or the “Company”) was incorporated in Delaware on December 22, 1997. Agile is a women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. The Company’s activities since inception have consisted principally of raising capital, performing research and development, including development of the Company’s lead product, Twirla, and more recently commercializing Twirla. The Company is headquartered in Princeton, New Jersey. The Company’s sole approved product, Twirla ® , competition from larger companies and compliance with FDA and other government regulations. If the Company does not successfully commercialize Twirla, it will be unable to generate recurring product revenue or achieve profitability. The Company has incurred operating losses and negative cash flows from operating activities each year since inception. As of June 30, 2022, the Company had an accumulated deficit of approximately The Company expects to continue to incur significant operating expenses for the foreseeable future in connection with its ongoing activities, as the Company: ​ ● maintains a sales and marketing infrastructure to support the continued commercialization of Twirla in the United States; ​ ● works towards completing its post-marketing evaluations of Twirla agreed upon with the FDA upon Twirla’s approval; ​ ● continues to evaluate additional line extensions for Twirla and initiates development of potential product candidates in addition to Twirla; ● maintains, leverages and expands the Company’s intellectual property portfolio; and ● maintains operational, financial and management information systems and personnel, including personnel to support the Company’s product development and future commercialization efforts. ​ The Company has financed its operations to date primarily through the issuance and sale of its common stock in both public and private offerings (see Note 8), private placements of its convertible preferred stock, venture loans, and non-dilutive grant funding. ​ Going Concern As of June 30, 2022, the Company had cash and cash equivalents of $13.0 million and a working capital deficit of $10.3 million. On July 6, 2022, the Company completed a best efforts public offering (the “Offering”) in which the Company raised 7,518,334 pre-funded warrants (“Series B pre-funded warrants”) to purchase 7,518,334 shares of common stock . Both the sale of shares of common stock and pre-funded warrants were accompanied by Series A-1 and Series A-2 warrants (together the “Series A warrants”) to purchase shares of common stock. The Company expects that its current liquidity is sufficient to fund operations through the end of 2022. The Company closely monitors its cash and cash equivalents and will have to raise additional capital to meet its projected operating requirements, including the continued commercialization of Twirla, exploring the advancement of its existing pipeline and its possible expansion through business development activities. The Company has generated losses since inception, used substantial cash in operations, has a working capital deficit at June 30, 2022 and anticipates it will continue to incur net losses for the foreseeable future. The Company’s future success depends on its ability to obtain additional capital and/or implement various strategic alternatives, and there can be no assurance that any financing can be realized by the Company, or if realized, what the terms of any such financing may be, or that any amount that the Company is able to raise will be adequate. Based upon the foregoing, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern through the 12 months following the date on which this Quarterly Report on Form 10-Q is filed. The Company continues to analyze various strategic alternatives, including refinancing alternatives, asset sales and mergers and acquisitions. The Company’s future success depends on its ability to raise additional capital as discussed above. The Company cannot be certain that these initiatives or raising additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company’s current stockholders will experience dilution. If the Company is unable to obtain funds when needed or on acceptable terms, the Company then may be unable to continue the commercialization of Twirla, and may also be required to cut operating costs, and forego future development and other opportunities. The unaudited financial statements as of June 30, 2022 have been prepared under the assumption that the Company will continue as a going concern for the next 12 months. The Company’s ability to continue as a going concern is dependent upon its uncertain ability to obtain additional capital, reduce expenditures and/or execute on its business plan and successfully commercialize Twirla. The unaudited financial statements as of June 30, 2022 do not include any adjustments that might result from the outcome of this uncertainty. If the Company is unable to continue as a going concern, it may have to liquidate its assets and may receive less than the value at which those assets are carried on the financial statements. Basis of Presentation The accompanying unaudited interim financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the audited financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 30, 2022. In the opinion of management, the unaudited interim financial statements reflect all adjustments, which are normal recurring adjustments, necessary for the fair presentation of the financial information for the interim periods presented. The results of operations for the three and six months ended June 30, 2022 are not necessarily indicative of the operating results for the full fiscal year or any future period. Certain expense classifications have been made to prior periods to conform with current reporting. The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company has incurred recurring losses and negative cash flows from operations. If the COVID-19 pandemic or other factors impact the Company’s current business plan or its ability to generate revenue from the launch of Twirla, the Company believes it has the ability to revise its commercial plans, including curtailing sales and marketing spending, to allow it to continue to fund its operations

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company’s complete listing of significant accounting policies is described in Note 2 to the Company’s audited financial statements as of December 31, 2021 included in its Annual Report on Form 10-K filed with the SEC. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, costs of product revenues, inventory reserves, the accounting for common stock warrants, stock-based compensation, and accounting for research and development costs. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Risks and Uncertainties While Twirla has been approved by the U.S. Food and Drug Administration, or FDA, other potential product candidates developed by the Company will require approval from the FDA prior to commercial sales. There can be no assurance that the Company’s other product candidates will receive the required approval. If the Company is denied approval or such approval is delayed, or is unable to obtain the necessary financing to complete development and approval, there could be a material adverse impact on the Company’s financial condition and results of operations. It should be noted that current public health threats could adversely affect the Company’s ongoing or planned business operations. In particular, the ongoing COVID-19 pandemic has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The most significant impacts to the Company’s business were encountered by sales representatives promoting Twirla in the field, as some offices limited opportunities for face-to-face interactions with healthcare providers. In many cases COVID-19 restrictions have recently eased, but re-implementation of such restrictions if necessary in the future may disrupt the Company’s business and/or could adversely affect the Company’s commercialization plans and results. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties with whom it engages, including personnel at third-party manufacturing facilities and other third parties with whom the Company conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct its business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on the Company. While to date the Company has been able to continue to execute its overall business plan, some of its business activities slowed and took longer to complete as the Company adjusted to the challenges of operating in a largely remote setting with its employees. While the Company has acclimated to a hybrid work model with its employees, another shut down necessitating work in a completely remote environment could result in delays to its business activities and commercialization plan. Overall, the Company recognizes the challenges of commercializing a new product in a pandemic, and it will continue to closely monitor events as they develop and plan for alternative and mitigating measures that it can implement if needed. Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. Cash and cash equivalents include money market funds that invest primarily in commercial paper and U.S. government and U.S. government agency obligations. The Company maintains balances with financial institutions in excess of the Federal Deposit Insurance Corporation limit. Trade Accounts Receivable and Allowances Trade accounts receivable are amounts owed to the Company by its customers for product that has been delivered. The trade accounts receivable are recorded at the invoice amount, less prompt pay and other discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses represents the Company’s estimate of losses over the life of the receivables. The Company evaluates forward looking economic factors and uses professional judgment to determine the allowance for credit losses. The credit loss reserves are reviewed and adjusted periodically. Credit loss reserves were not material as of June 30, 2022 or December 31, 2021. ​ Trade accounts receivable are aged based on the contractual payment terms. When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists. Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments Other financial instruments, including accounts receivable, accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature. Inventory Inventory is valued utilizing the weighted average costing method. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management’s current knowledge with respect to inventory levels, planned production and sales volume assumptions. ​ Property and Equipment Property and equipment, consisting of manufacturing equipment, office equipment and computer equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to earnings in the period in which costs are incurred. Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment , the Company’s policy is to review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. At June 30, 2022, no indicators of impairment were present. Research and Development Expenses Research and development expenses consist primarily of costs related to personnel, including salaries and other personnel-related expenses, expenses related to manufacturing, clinical trial expenses, consulting fees and support services used in product development. All research and development costs are charged to operations as incurred in accordance with ASC 730, Research and Development In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received. Advertising Costs The Company has elected to expense advertising costs when incurred. Advertising costs totaled ​ Deferred Financing Costs Costs directly attributable to the Company’s senior secured term loan (see Note 7) are deferred and reported as a reduction of the related term loan. These costs represent a 1% facility fee paid directly to the lender, legal fees and other costs related to the term loan and are being amortized over the term of the loan. Amortization of deferred financing costs charged to interest expense was $66,000 and $69,000 for the three months ended June 30, 2022 and 2021, respectively, and was $139,000 for each of the six months ended June 30, 2022 and 2021. Concentrations of Credit Risk Financial instruments which potentially subject the Company to credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest-bearing accounts in United States financial institutions, the balances of which exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has Major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three months ended June 30, 2022, the Company had sales to customers that individually accounted for more than 10% of its total revenue. These customers had sales of of total revenues in the quarter. Accounts receivable related to these Revenue Recognition The Company recognizes revenue from the sale of its product, Twirla, in accordance with ASC 606, Revenue from Contracts with Customers ​ In accordance with ASC 606, the Company recognizes revenue at the point in time when its performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist primarily of wholesale distributors. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable and Allowance policy. ​ The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. ​ Twirla is sold to customers at the Wholesale Acquisition Cost (WAC). However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration items reduce revenue and include the following: ​ • Distribution services fees; • Prompt pay and other discounts; • Product returns; • Chargebacks; • Rebates; and • Co-payment assistance. ​ An estimate for each variable consideration item is made and is recorded in conjunction with the revenue being recognized. Generally, if the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed, and adjustments are made if necessary. Any adjustments made to these provisions would affect net product revenue and earnings in the current period. ​ In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relies on industry standard data and trend analysis as historical sales data for Twirla are not yet available based on the December 2020 launch date. Once historical data becomes available, the Company will incorporate Twirla specific data into its estimates of variable consideration. ​ The Company uses the following specific considerations to estimate variable consideration. ​ Distribution services fees – The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase amount. The Company records these fees as contra trade accounts receivable on the balance sheet. ​ Prompt pay and other discount ​ The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recorded. ​ Product returns ​ Chargebacks – Certain government entities and indirect customers (for example group purchasing organizations and 340B covered entities) will be able to purchase the product at a price discounted below WAC. The difference between the price paid by the government or other indirect purchaser and the price paid by the wholesale distributor will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra trade accounts receivable on the balance sheet. ​ Rebates ​ Co-payment assistance Company estimates the amount of co-payment assistance based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Co-payment assistance estimates are recorded as other current liabilities on the balance sheet. ​ Provisions for the revenue reserves described above totaled for the six months ending June 30, 2022 and 2021, respectively. As of June 30, 2022, reserves on the balance sheet associated with variable consideration were million. ​ Warrants The Company accounts for its warrants to purchase common stock in accordance with ASC 480, Distinguishing Liabilities from Equity . In connection with entering into a senior secured term loan facility in February 2020, the Company issued warrants to purchase 35,000 shares of its common stock. In connection with an amendment to that facility in February 2021, the Company issued a warrant to purchase 11,250 shares of the Company’s common stock. These warrant instruments qualify for equity classification and have been allocated based upon the relative fair value of the base instrument and the warrant. These warrants are subject to repricing in the event of an offering of securities at a price lower than the existing strike price before December 31, 2022. See Note 7 for additional information. In connection with an underwritten public offering completed in October 2021, the Company issued warrants to purchase 333,333 shares of its common stock. This offering also triggered an adjustment to the exercise price of the existing warrants mentioned above, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. S In connection with a registered direct offering completed in March 2022, the Company issued warrants to purchase 1,242,813 shares of its common stock. This offering also triggered an adjustment to the exercise price of the existing warrants mentioned above, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. S In connection with a letter agreement and waiver entered into with an investor on April 2022, the Company issued warrants to purchase 212,188 shares of common stock, subject to adjustment thereunder. See Note 8 for additional information. In connection with a public offering completed in July 2022, the Company issued warrants to purchase 54,666,665 shares of its common stock. See Note 11 for additional information. This offering also triggered an adjustment to the exercise price of the existing warrants in connection with the senior secured term loan facility mentioned above, which resulted in a reduction of the strike price for these warrants. Income Taxes ​ The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes The Company has adopted the authoritative guidance on accounting for and disclosure of uncertainty in tax positions which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The Company has no uncertain tax positions as of June 30, 2022 that qualify for either recognition or disclosure in the financial statements under this guidance. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation . The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to no less than the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company elects to account for forfeitures when they occur. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital. The Company also awards restricted stock units (“RSUs”) to employees and its board of directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested RSUs and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for both the three and six months ended June 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 2021 Common stock warrants 1,834,584 46,250 ​ Unvested restricted stock units 7,125 6,342 ​ Common stock options ​ 288,944 ​ 258,808 ​ Total 2,130,653 311,400 ​ ​ Recent Accounting Pronouncements In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). The guidance is effective for the Company on January 1, 2022. The adoption of this standard did not have a material impact on its financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Measurements
Fair Value Measurements	3. Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Assets and liabilities that are measured at fair value are reported using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: ● Level 1 — Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets consist of cash and cash equivalents. The Company has no Level 1 liabilities. ● Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted market prices for similar assets or liabilities in active markets or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities. The Company has no Level 2 assets or liabilities. ● Level 3 — Unobservable inputs that are supported by little or no market data and which require internal development of assumptions about how market participants price the fair value of the assets or liabilities. The Company has no Level 3 assets or liabilities. The following table sets forth the Company’s financial instruments measured at fair value by level within the fair value hierarchy as of June 30, 2022 and December 31, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 13,027 ​ $ — ​ $ — Total assets at fair value ​ $ 13,027 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,143 ​ $ — ​ $ — Total assets at fair value ​ $ 19,143 ​ $ — ​ $ — ​ There were no transfers between Level 1, 2 or 3 during 2022 or 2021.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2022
Prepaid Expenses and Other Current Assets
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2022 2021 Prepaid insurance ​ $ 199 ​ $ 775 ​ Other ​ 817 ​ 1,508 ​ Total prepaid expenses and other current assets ​ $ 1,016 ​ $ 2,283 ​ ​

Accrued Liabilities

Accrued Liabilities	6 Months Ended
	Jun. 30, 2022
Accrued Liabilities
Accrued Liabilities	5. Accrued Liabilities Accrued liabilities consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2022 2021 Accrued compensation ​ $ 1,545 ​ $ 2,086 ​ Accrued professional fees and other ​ 2,332 ​ 1,477 ​ Total accrued liabilities ​ $ 3,877 ​ $ 3,563 ​ ​

Leases

Leases	6 Months Ended
	Jun. 30, 2022
Leases
Leases	6. Leases The Company has no finance leases and one operating lease for its corporate headquarters in Princeton, NJ. The current lease commenced on December 1, 2021 and terminates on March 31, 2025. The lease provides the Company with an . Under the terms of the lease, the Company pays base annual rent subject to a fixed dollar amount increase each year, a fixed monthly charge for electricity, and other normal operating expenses such as taxes, repairs, and maintenance. The Company evaluates renewal options at lease inception and on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities. The lease does not require variable lease payments, residual value guarantees or restrictive covenants. The lease does not provide an implicit rate, therefore the Company used its incremental borrowing rate as the discount rate when measuring the operating lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease. Operating lease expense was for the three months ended June 30, 2022 and 2021, respectively. Operating lease expense was $ for the six months ended June 30, 2022 and 2021, respectively. Operating cash flows used for operating leases during the three months ended June 30, 2022 and 2021 were respectively. Operating cash flows used for operating leases during the 6 months ended June 30, 2022 and 2021 were respectively. As of June 30, 2022, the weighted-average remaining lease term was Future minimum lease payments under non-cancellable leases as of June 30, 2022 were as follows (in thousands): ​ ​ ​ ​ ​ 2022 ​ $ 132 2023 ​ ​ 390 2024 ​ ​ 398 2025 ​ 101 Total ​ $ 1,021 Less: Interest ​ (152) Present value of lease liability ​ $ 869 ​

Credit Agreement and Guaranty

Credit Agreement and Guaranty	6 Months Ended
	Jun. 30, 2022
Credit Agreement and Guaranty
Credit Agreement and Guaranty	7. Credit Agreement and Guaranty On February 10, 2020 (the “Closing Date”), the Company entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings III, LP, a related party (“Perceptive”), for a senior secured term loan credit facility of up to million tranche was to be available to the Company based on the achievement of a revenue milestone by December 31, 2021. The Company did not achieve that milestone and that tranche is no longer available to it. On February 26, 2021 the Perceptive Credit Agreement was amended (“Amended Perceptive Credit Agreement”) by creating a fourth tranche of million that was to be available to the Company based on the achievement of a revenue milestone. The Company did not achieve that milestone and that tranche is no longer available to it. On January 7, 2022, the Company and Perceptive entered into a second amendment to the Amended Perceptive Credit Agreement (the “Second Amendment”). The Second Amendment waives the Company’s obligations to comply with certain financial covenants relating to minimum revenue requirements through September 30, 2022 and to file financial statements along with its Annual Report on Form 10-K that are not subject to any “going concern” qualification. The effectiveness of the Second Amendment is conditioned upon the satisfaction of certain conditions, including the Company raising additional capital and prepaying a portion of its outstanding debt. On January 7, 2022, the Company prepaid $5.0 million of the outstanding debt, and in accordance with the terms of the Second Amendment, no prepayment premium was due. On March 10, 2022, the Company and Perceptive entered into a third amendment to the Perceptive Credit Agreement, as amended (the “Third Amendment”). The Third Amendment waived the Company’s obligations to (1) comply with certain financial covenants relating to minimum revenue requirements through September 30, 2022, conditioned upon the satisfaction of certain conditions, including the Company raising additional capital and prepaying a portion of its outstanding debt by April 30, 2022 and (2) file financial statements along with its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 that are not subject to any “going concern” qualification. On May 11, 2022, the Company and Perceptive entered into a fourth amendment to the Perceptive Credit Agreement, as amended (the “Fourth Amendment”). The Fourth Amendment waived the Company’s obligations to comply with certain financial covenants relating to minimum revenue requirements through September 30, 2022, conditioned upon the satisfaction of certain conditions, including raising additional capital and prepaying a portion of its outstanding debt by May 31, 2022. On July 8, 2022, the Company prepaid $5.0 million of the outstanding debt, and in accordance with the terms of the Fourth Amendment, no prepayment premium was due. On July 25, 2022, the Company entered into a fifth amendment to the Perceptive Credit Agreement, as amended (the “Fifth Amendment”). Pursuant to the Fifth Amendment, Perceptive agreed to release its security interest in certain assets being transferred from the Company to Corium in connection with an amendment to the Company’s Manufacturing and Commercialization Agreement with Corium and waive the Company’s obligations to comply with certain financial covenants through the end of 2022. In exchange, the Company agreed to prepay $7 million of outstanding principal under the Perceptive Credit Agreement using the proceeds of recent sales under the Company’s ATM program with H.C. Wainwright & Co., LLC. Such payment was made on July 25, 2022. ​ The facility will mature on February 10, 2024 (“Maturity Date”). Pursuant to the Fifth Amendment, beginning August 31, 2022, the Company is scheduled to make monthly principal payments in an amount equal to until February 10, 2024, at which time all remaining principal amount outstanding is due. ​ Borrowings under the Fifth Amendment will accrue interest at an annual rate equal to . The rate of interest in effect as of the Closing Date and at June 30, 2022 was 11.75% . Upon the occurrence and during the continuance of any event of default under the Fifth Amendment, the interest rate automatically increases by 3.0% per annum. ​ The Company may prepay any outstanding loans in whole or in part. Any such prepayment of the loans is subject to a prepayment premium of ​ All of the Company’s obligations under the Fifth Amendment are secured by a first-priority lien and security interest in substantially all of the Company’s tangible and intangible assets, including intellectual property. ​ The Fifth Amendment contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customary for similar financings. The negative covenants restrict or limit the ability of the Company to, among other things and subject to certain exceptions contained in the Amended Perceptive Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company’s business activities; make certain investments or restricted payments (each as defined in the Amended Perceptive Credit Agreement); change its fiscal year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company’s ability to make loan repayments under the Amended Perceptive Credit Agreement. In addition, the Company must (i) at all times prior to the Maturity Date maintain a minimum cash balance of $3.0 million; and (ii) as of the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2022, report revenues for the trailing 12-month period that exceed the amounts set forth in the Amended Perceptive Credit Agreement, which range from $53.0 million for the fiscal quarter ending December 31, 2022 to $87.1 million for the fiscal quarter ending December 31, 2023. In the event the Company does not pay off the remainder of the outstanding principal under the facility, the Company will need to negotiate for a waiver of its obligations to comply with the covenants relating to revenues for Twirla in the first quarter of 2023. ​ In connection with the Perceptive Credit Agreement, the Company issued to Perceptive two warrants to purchase an aggregate of 35,000 shares of the Company’s common stock (together, the “2020 Perceptive Warrants”). The first warrant is exercisable for 17,500 shares of common stock at an exercise price of $149.60 per share. The second warrant is exercisable for 17,500 shares of common stock at an exercise price of $186.80 per share. The 2020 Perceptive Warrants expire on February 10, 2027. In connection with the Amended Perceptive Credit Agreement, the Company issued to Perceptive a warrant to purchase 11,250 shares of the Company’s common stock (the “2021 Perceptive Warrant” and, together with the 2020 Perceptive Warrants, the “Perceptive Warrants”) at an exercise price of $114.80 per share. The 2021 Perceptive Warrant expires on February 26, 2028. The Perceptive Warrants contain anti-dilution provisions and other warrant holder protections, and are not exercisable to the extent that Perceptive would beneficially own more than 19.99% ​ As a result of the public offering of the Company’s common stock completed in October 2021 (see Note 8), the anti-dilution provision of the Perceptive Warrants was triggered resulting in a reduction of the strike price for the Perceptive Warrants. Warrants to purchase 17,500 shares of common stock that had an exercise price of $186.80 per share were reduced to $141.60 per share, warrants to purchase 17,500 shares of common stock that had an exercise price of $149.60 per share were reduced to $115.20 per share, and warrants to purchase 11,250 shares of common stock that had an exercise price of $114.80 per share were reduced to $90.80 per share. ​ As a result of the registered direct offering completed in March 2022 (see Note 8), the anti-dilution provision of the Perceptive Warrants was again triggered resulting in a further reduction of the strike price for the Perceptive Warrants. Warrants to purchase 17,500 shares of common stock that had an adjusted exercise price of $141.60 per share were reduced to $105.52 per share, warrants to purchase 17,500 shares of common stock that had an adjusted exercise price of $115.20 per share were reduced to $86.61 per share, and warrants to purchase 11,250 shares of common stock that had an adjusted exercise price of $90.80 per share were reduced to $69.13 per share. ​ As a result of the public offering of the Company’s common stock completed in July 2022 (see Note 8), the anti-dilution provision of the Perceptive Warrants was again triggered resulting in a reduction of the strike price for the Perceptive Warrants. Warrants to purchase 17,500 shares of common stock that had an exercise price of $105.52 per share were reduced to $14.90 per share, warrants to purchase 17,500 shares of common stock that had an exercise price of $86.61 per share were reduced to $12.37 per share, and warrants to purchase 11,250 shares of common stock that had an exercise price of $69.13 per share were reduced to $10.03 per share. ​ The Company allocated the proceeds of $20.0 million in accordance with ASC 470 based on the relative fair values of the debt and the Perceptive Warrants. The relative fair value of the Perceptive Warrants of approximately $3.6 million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The significant assumptions used in preparing the option pricing model for valuing the Perceptive Warrants issued include (i) volatility (70.0%), (ii) risk free interest rate of 1.47% (estimated using treasury bonds with a 7-year life), (iii) strike prices of $149.60 and $186.80 for the common stock warrants, (iv) fair value of common stock ($160.40) and (v) expected life (7 years). The fair value of the 2021 Perceptive Warrants of approximately $1.1 million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the debt. The significant assumptions used in preparing the option pricing model for valuing the 2021 Perceptive Warrants issued include (i) volatility (103.5%), (ii) risk free interest rate of 1.15% (estimated using treasury bonds with a 7-year life), (iii) strike price of $114.80 for the common stock warrant, (iv) fair value of common stock ($114.80) and (v) expected life (7 years). The fair value of the warrants as well as the debt issue costs incurred in connection with the entry into the Perceptive Credit Agreement, including a facility fee of 1% of the total amount of loans available under the facility, are presented as a direct deduction from the carrying amount of the term loan on the consolidated balance sheet as detailed below (in thousands). ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2022 ​ 2021 Notes payable $ 15,000 ​ $ 20,000 Debt issuance costs ​ ​ (412) ​ ​ (550) Warrant discount ​ ​ (1,958) ​ ​ (2,617) Total debt ​ $ 12,630 ​ $ 16,833 Less, current portion ​ ​ 12,630 ​ ​ 16,833 Long-term debt, less current portion ​ $ — ​ $ — ​ The fair value of the warrants and the debt issue costs are being amortized utilizing the effective interest method over the term of the loan. The Company recorded interest expense for the amortization of the fair value of the warrants and debt issue costs of ​ ​

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity
Stockholders' Equity	8. Stockholders’ Equity On January 7, 2022, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance from 150,000,000 shares to 300,000,000 shares. On April 26, 2022, the Company filed with the Secretary of State of the State of Delaware a certificate of amendment, or the Certificate of Amendment, to the Company’s Amended and Restated Certificate of Incorporation, which became effective on April 26, 2022 . The Certificate of Amendment implemented the Reverse Stock Split. On the effective date of April 26, 2022, the number of the Company’s issued and outstanding shares of common stock was decreased from and the par value remained unchanged. fractional shares were issued as a result of the Reverse Stock Split. Stockholders who would otherwise have been entitled to receive a fractional share received a cash payment in lieu thereof. The Reverse Stock Split affected all shares of the Company’s common stock outstanding immediately prior to the effective date of the Reverse Stock Split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans. In addition, the Reverse Stock Split effected a reduction in the number of shares of common stock issuable upon the exercise of stock options, restricted stock units, or warrants outstanding. Shelf Registration Statement On October 2, 2020, the Company filed a universal shelf registration statement with the SEC for the issuance of common stock, preferred stock, warrants, rights, debt securities and units up to an aggregate amount of $200.0 million (the “2020 Shelf Registration Statement”). On October 14, 2020, the 2020 Shelf Registration Statement was declared effective by the SEC. In the future, the Company may periodically offer one or more of these securities in amounts, prices and terms to be announced when and if the securities are offered. At the time any of the securities covered by the 2020 Shelf Registration Statement are offered for sale, a prospectus supplement will be prepared and filed with the SEC containing specific information about the terms of any such offering. Public Offerings ​ In October 2021, the Company completed a public offering of 666,666 shares of its common stock and warrants to purchase 333,333 shares of its common stock at a combined price of $34.00 per share of common stock and one-half of a warrant to purchase one share of common stock. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately $21.1 million. In July 2022, the Company completed a public offering of (1) 19,148,332 shares of its common stock and warrants to purchase 38,296,664 shares of its common stock at a combined price of $0.90 per share of common stock and warrants and (2) 7,518,334 pre-funded warrants to purchase 7,518,334 shares of its common stock and warrants to purchase 15,036,668 shares of its common stock at at a combined price of $0.8999 per share of common stock and pre-funded warrant. Proceeds from the public offering, net of underwriting discounts, commissions and offering expenses were approximately $22.2 million. See Note 11 for additional information. ATM Sales Agreement In March 2021, the Company entered into a common stock sales agreement (the “2021 ATM Agreement”) under which the Company may sell up to an aggregate of $50.0 million in gross proceeds through the sale of shares of common stock from time to time in “at-the-market” equity offerings (as defined in Rule 415 promulgated under the Securities Act of 1933, as amended). The Company agreed to pay a commission of up to 3% of the gross proceeds of any common stock sold under the 2021 ATM Agreement. During the year ended December 31, 2021, the Company issued and sold 172,879 shares of common stock under the 2021 ATM Agreement resulting in net proceeds to the Company of approximately $9.3 million. On January 10, 2022, the Company filed a prospectus supplement to its 2020 Shelf Registration Statement registering an at-the-market offering program (the “January 2022 ATM”) the Company entered into for the sale of up to $50.0 million of shares of its common stock. The Company agreed to pay a commission of up to proceeds to the Company of approximately $0.3 million. On April 26, 2022, the Company terminated the January 2022 ATM. ​ On April 27, 2022, the Company entered into a new at-the-market offering program with H.C. Wainwright LLC (the “Sales Agent”), and Co. (“April 2022 ATM”), under which the Company may, from time to time in its sole discretion, issue and sell through or to the Sales Agent, acting as the Company’s agent, up to $12,841,000 of shares of the Company’s common stock (the “Placement Shares”). The Company agreed to pay the Sales Agent a commission of up to 3.0% of the gross sales proceeds of any Placement Shares sold under the April 2022 ATM. Through June 30, 2022, the Company issued and sold a total of ​ Registered Direct Offering On March 14, 2022, the Company filed a prospectus supplement to its 2020 Shelf Registration Statement registering a direct offering (the “2022 Preferred Stock Offering”) of 2,425 shares of Series A convertible preferred stock (the “Series A Preferred Stock”) and 2,425 shares of Series B convertible preferred stock (the “Series B Preferred Stock”) and Series A warrants (the “Series A Warrants”) to purchase up to an aggregate of 606,250 shares of the common stock of the Company and Series B warrants (the “Series B Warrants”) to purchase up to an aggregate of 606,250 shares of common Stock. Each share of Series A Preferred Stock and Series B Preferred Stock has a stated value of $1,000 per share and a conversion price of $8.00 per share. The shares of preferred stock issued in the 2022 Preferred Stock Offering are convertible into an aggregate of 606,250 shares of common stock. The Series A Warrants have an exercise price of $10.40 per share, will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The Series B Warrants have an exercise price of $10.40 per share, will become exercisable six months following the date of issuance, and will expire one and one -half years following the initial exercise date. million. A portion of the placement’s agents fees included warrants to purchase The Company allocated the net proceeds of $4.1 million in accordance with ASC 470 based on the relative fair values of the preferred stock and the Series A Warrants and Series B Warrants (collectively, the “Warrants”). The relative fair value of the Warrants of approximately $2.1 million at the time of issuance, which was determined using the Black-Scholes option-pricing model, was recorded as additional paid-in capital and reduced the carrying value of the preferred stock. The significant assumptions used in preparing the option pricing model for valuing the Warrants issued include (i) volatility of On March 15, 2022, 2,425 shares of the Series A Preferred Stock was converted into 303,125 shares of the Company’s common stock. On April 4, 2022, 2,425 shares of the Series B Preferred Stock was converted into 303,125 shares of the Company’s common stock. On April 25, 2022, the Company entered into a letter agreement and waiver (“Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), pursuant to which Armistice consented to the Company entering into and effecting an at-the-market (“ATM”) offering facility. On March 14, 2022 the Company entered into the 2022 Preferred Stock Offering with Armistice, under which agreement, the Company was restricted from entering into and effecting an ATM offering facility until the 180-day anniversary of the Closing Date. Pursuant to the Letter Agreement, the Company issued to Armisitice a new common stock purchase warrant (“New Warrant”), on the same terms and conditions as the Series A Warrants, provided that such New Warrant shall be exercisable into 212,188 warrant shares, subject to adjustment thereunder. The Series A Warrants have an exercise price of $10.40 per share, and will become exercisable six months following the date of issuance, and will expire 5 years following the initial exercise date. The New Warrant is exercisable 6 months after the date of the Letter Agreement. Stock-Based Compensation Expense Stock-based compensation expense was allocated as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 2021 ​ 2022 2021 Cost of goods sold ​ $ 31 ​ $ 75 ​ $ 75 ​ $ 135 ​ Research and development ​ ​ 91 ​ ​ 121 ​ ​ 194 ​ ​ 228 ​ Selling and marketing ​ ​ 40 ​ ​ 43 ​ ​ 80 ​ ​ 78 ​ General and administrative ​ 507 ​ 604 ​ 1,084 ​ 1,144 ​ Total ​ $ 669 ​ $ 843 ​ $ 1,433 ​ $ 1,585 ​ ​

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Taxes
Income Taxes	9. Income Taxes The Company has participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by The New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused NOLs and unused research and development credits to sell these tax benefits for at least 80% of the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The Program is administered by The New Jersey Economic Development Authority and the New Jersey Department of the Treasury’s Division of Taxation. The Company had previously reached the maximum lifetime benefit of $15.0 million under the historical Program, however in January 2021 the Program was amended to extend the maximum lifetime benefit to $20.0 million. The Company received final approval in March 2022 for ​

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies
Commitments and Contingencies	10. Commitments and Contingencies The Company has several firm purchase commitments, primarily related to the manufacture and supply of Twirla and the supply of a field force of sales representatives to provide certain detailing services, sales operation services, compliance services, and training services. Future firm purchase commitments under these agreements, the last of which ends in 2033 total million. This amount does not represent all of the Company’s anticipated purchases in the future, but instead represents only purchases that are the subject of contractually obligated minimum purchases. The minimum commitments disclosed are determined based on non-cancelable minimum spend in 2021 or termination amounts. Additionally, the Company purchases products and services as needed with no firm commitment. In April 2020, we entered into a manufacturing and commercialization agreement with Corium, Inc., which we refer to as the Corium Agreement. Under the Corium Agreement, the Company has a requirement to order quarterly minimum volumes of approximately million of product. In the event that the Company does not order the minimum volume, the Company is required to pay an additional fee equal to twenty-five percent ( per unit fee as a penalty for all units ordered during the period. Based on current demand expectations for Twirla, the Company did not expect to meet the minimum volume order for the balance of 2022 and would be subject to the additional fee on future purchases. On July 25, 2022 the Company and Corium entered into Amendment No. 1 to the Corium Agreement that is designed to restructure the contract minimums applicable to the purchase of manufactured Twirla. See Note 11 for additional information. The Company records a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. An unfavorable outcome to any legal matter, if material, could have an adverse effect on the Company's operations or its financial position. As of June 30, 2022, the Company has not recorded a provision for any contingent losses.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2022
Subsequent Event.
Subsequent Event	11. Subsequent Events On July 6, 2022, the Company completed the Offering. In connection with the Offering, the Company issued common stock, an aggregate of Series A-1 warrants to purchase 26,666,666 shares of common stock and Series A-2 warrants to purchase 26,666,666 shares of common stock. As compensation to H.C. Wainwright & Co., LLC (the “Placement Agent”), as the exclusive placement agent in connection with the Offering, the Company paid the Placement Agent a cash fee of The Company received net proceeds of approximately On July 25, 2022, the Company entered into Amendment No. 1 (“the Amendment”) to the Corium Manufacturing and Commercialization Agreement (the “Corium Agreement”). The Amendment is designed to restructure the minimums applicable to the purchase of manufactured Twirla and other services provided by Corium, transfer equipment ownership to Corium to support the manufacture of Twirla and extend the term of the Corium Agreement. Pursuant to the Amendment, the parties agreed to adjust the process for Agile providing Corium certain binding and non-binding forecasts required under the Corium Agreement. Additionally, Corium will not enforce the original quantity mininimums in the Corium Agreement, which are waived and replaced by new minimums that are based on Corium’s revenue for product purchased by Agile, expiring raw materials, and other services billed by Corium to support batch production and release. The guaranteed minimum revenue requirement for 2022 is million for 2024 and each year thereafter. In the event that the Company does not meet the guaranteed minimum revenue requirements in any given year, the Company will be required to make additional payments to Corium for the shortfall. The Company agreed to make certain monthly supplemental payments to Corium through December 2023, which payments are eligible to be retroactively reduced based upon product orders placed by the Company during 2022 and 2023 meeting certain designated thresholds. In connection with the supplemental payments, Corium will retain the proceeds for the sale of certain raw materials to which the Company would otherwise have economic right to offset such supplemental payments. Further, the Company agreed to reimburse Corium for any unused raw materials in the event the Company’s actual product requirements are lower than initially forecasted. Pursuant to the Amendment, the term of the Corium Agreement was extended to December 31, 2033. Pursuant to the Amendment, the parties agreed to transfer ownership of certain manufacturing equipment used in the manufacture of Twirla from the Company to Corium under a Bill of Sale dated July 25, 2022 (the “Bill of Sale”). ​ On July 25, 2022, the Company and Perceptive entered into Such payment was made on July 25, 2022. Pursuant to the Fifth Amendment, beginning August 31, 2022, the Company is scheduled to make monthly principal payments in an amount equal to ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates and judgments on historical experience and various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of revenue and expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, revenue recognition, costs of product revenues, inventory reserves, the accounting for common stock warrants, stock-based compensation, and accounting for research and development costs. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates.
Risks and Uncertainties	Risks and Uncertainties While Twirla has been approved by the U.S. Food and Drug Administration, or FDA, other potential product candidates developed by the Company will require approval from the FDA prior to commercial sales. There can be no assurance that the Company’s other product candidates will receive the required approval. If the Company is denied approval or such approval is delayed, or is unable to obtain the necessary financing to complete development and approval, there could be a material adverse impact on the Company’s financial condition and results of operations. It should be noted that current public health threats could adversely affect the Company’s ongoing or planned business operations. In particular, the ongoing COVID-19 pandemic has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The most significant impacts to the Company’s business were encountered by sales representatives promoting Twirla in the field, as some offices limited opportunities for face-to-face interactions with healthcare providers. In many cases COVID-19 restrictions have recently eased, but re-implementation of such restrictions if necessary in the future may disrupt the Company’s business and/or could adversely affect the Company’s commercialization plans and results. The Company cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if the Company or any of the third parties with whom it engages, including personnel at third-party manufacturing facilities and other third parties with whom the Company conducts business, were to experience shutdowns or other business disruptions, the Company’s ability to conduct its business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on the Company. While to date the Company has been able to continue to execute its overall business plan, some of its business activities slowed and took longer to complete as the Company adjusted to the challenges of operating in a largely remote setting with its employees. While the Company has acclimated to a hybrid work model with its employees, another shut down necessitating work in a completely remote environment could result in delays to its business activities and commercialization plan. Overall, the Company recognizes the challenges of commercializing a new product in a pandemic, and it will continue to closely monitor events as they develop and plan for alternative and mitigating measures that it can implement if needed.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less when purchased to be cash equivalents. All cash and cash equivalents are held in United States financial institutions. Cash and cash equivalents include money market funds that invest primarily in commercial paper and U.S. government and U.S. government agency obligations. The Company maintains balances with financial institutions in excess of the Federal Deposit Insurance Corporation limit.
Trade Accounts Receivable and Allowances	Trade Accounts Receivable and Allowances Trade accounts receivable are amounts owed to the Company by its customers for product that has been delivered. The trade accounts receivable are recorded at the invoice amount, less prompt pay and other discounts, chargebacks, and an allowance for credit losses, if any. The allowance for credit losses represents the Company’s estimate of losses over the life of the receivables. The Company evaluates forward looking economic factors and uses professional judgment to determine the allowance for credit losses. The credit loss reserves are reviewed and adjusted periodically. Credit loss reserves were not material as of June 30, 2022 or December 31, 2021. ​ Trade accounts receivable are aged based on the contractual payment terms. When the collectability of an invoice is no longer probable, the Company will create a reserve for that specific receivable. If a receivable is determined to be uncollectible, it is charged against the general credit loss reserve or the reserve for the specific receivable, if one exists.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments Other financial instruments, including accounts receivable, accounts payable and accrued liabilities, are carried at cost, which approximates fair value given their short-term nature.
Inventory	Inventory Inventory is valued utilizing the weighted average costing method. The Company records an inventory reserve for losses associated with dated, expired, excess or obsolete items. This reserve is based on management’s current knowledge with respect to inventory levels, planned production and sales volume assumptions. ​
Property and Equipment	Property and Equipment Property and equipment, consisting of manufacturing equipment, office equipment and computer equipment, is stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Expenditures incurred after the fixed assets have been put into operation, such as repairs and maintenance, are charged to earnings in the period in which costs are incurred.
Long-Lived Assets	Long-Lived Assets In accordance with ASC 360, Property, Plant and Equipment , the Company’s policy is to review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. At June 30, 2022, no indicators of impairment were present.
Research and Development Expense	Research and Development Expenses Research and development expenses consist primarily of costs related to personnel, including salaries and other personnel-related expenses, expenses related to manufacturing, clinical trial expenses, consulting fees and support services used in product development. All research and development costs are charged to operations as incurred in accordance with ASC 730, Research and Development In certain circumstances, the Company is required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are deferred and are expensed when the activity has been performed or when the goods have been received.
Advertising Costs	Advertising Costs The Company has elected to expense advertising costs when incurred. Advertising costs totaled
Deferred Financing Costs	Deferred Financing Costs Costs directly attributable to the Company’s senior secured term loan (see Note 7) are deferred and reported as a reduction of the related term loan. These costs represent a 1% facility fee paid directly to the lender, legal fees and other costs related to the term loan and are being amortized over the term of the loan. Amortization of deferred financing costs charged to interest expense was $66,000 and $69,000 for the three months ended June 30, 2022 and 2021, respectively, and was $139,000 for each of the six months ended June 30, 2022 and 2021.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments which potentially subject the Company to credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. The Company invests its cash, cash equivalents and marketable securities in debt instruments and interest-bearing accounts in United States financial institutions, the balances of which exceed federally insured limits. The Company has not recognized any losses from credit risks on such accounts. The Company mitigates credit risk by limiting the investment type and maturity to securities that preserve capital, maintain liquidity and have a high credit quality. The Company has Major customers of the Company are defined as those constituting greater than 10% of its total revenue. In the three months ended June 30, 2022, the Company had sales to customers that individually accounted for more than 10% of its total revenue. These customers had sales of of total revenues in the quarter. Accounts receivable related to these
Revenue Recognition	Revenue Recognition The Company recognizes revenue from the sale of its product, Twirla, in accordance with ASC 606, Revenue from Contracts with Customers ​ In accordance with ASC 606, the Company recognizes revenue at the point in time when its performance obligation is satisfied by transferring control of the promised goods or services to a customer. In accordance with the Company’s contracts with customers, control of the product is transferred upon the conveyance of title, which occurs when the product is sold to and received by a customer. The Company’s customers are located in the United States and consist primarily of wholesale distributors. Trade accounts receivable due to the Company from contracts with its customers are stated separately in the balance sheet, net of various allowances as described in the Trade Accounts Receivable and Allowance policy. ​ The amount of revenue recognized by the Company is equal to the amount of consideration that is expected to be received from the sale of product to its customers. Revenue is only recognized when it is probable that a significant reversal will not occur in future periods. To determine whether a significant reversal will occur in future periods, the Company assesses both the likelihood and magnitude of any such potential reversal of revenue. ​ Twirla is sold to customers at the Wholesale Acquisition Cost (WAC). However, the Company records product revenue, net of reserves for applicable variable consideration. These types of variable consideration items reduce revenue and include the following: ​ • Distribution services fees; • Prompt pay and other discounts; • Product returns; • Chargebacks; • Rebates; and • Co-payment assistance. ​ An estimate for each variable consideration item is made and is recorded in conjunction with the revenue being recognized. Generally, if the estimated amount is payable to a customer, it is recorded as a reduction to accounts receivable. If the estimated amount is payable to an entity other than a customer, it is recorded as a current liability. An estimated amount of variable consideration may differ from the actual amount. At each balance sheet date, these provisions are analyzed, and adjustments are made if necessary. Any adjustments made to these provisions would affect net product revenue and earnings in the current period. ​ In accordance with ASC 606, the Company must make significant judgments to determine the estimate for certain variable consideration. For example, the Company must estimate the percentage of end-users that will obtain the product through public insurance such as Medicaid or through private commercial insurance. To determine these estimates, the Company relies on industry standard data and trend analysis as historical sales data for Twirla are not yet available based on the December 2020 launch date. Once historical data becomes available, the Company will incorporate Twirla specific data into its estimates of variable consideration. ​ The Company uses the following specific considerations to estimate variable consideration. ​ Distribution services fees – The Company pays distribution service fees to its wholesale distributors. These fees are a contractually fixed percentage of WAC and are calculated at the time of sale based on the purchase amount. The Company records these fees as contra trade accounts receivable on the balance sheet. ​ Prompt pay and other discount ​ The Company may also give other discounts to its customers to incentivize purchases and promote customer loyalty. The terms of such discounts may vary by customer. These discounts reduce gross product revenue at the time the revenue is recorded. ​ Product returns ​ Chargebacks – Certain government entities and indirect customers (for example group purchasing organizations and 340B covered entities) will be able to purchase the product at a price discounted below WAC. The difference between the price paid by the government or other indirect purchaser and the price paid by the wholesale distributor will be charged back to the Company. The Company estimates the amount in chargebacks based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Estimated chargebacks are recorded as contra trade accounts receivable on the balance sheet. ​ Rebates ​ Co-payment assistance Company estimates the amount of co-payment assistance based on the expected number of claims and related cost that is associated with the revenue being recognized for product that remains in the distribution channel at the end of each reporting period. Co-payment assistance estimates are recorded as other current liabilities on the balance sheet. ​ Provisions for the revenue reserves described above totaled for the six months ending June 30, 2022 and 2021, respectively. As of June 30, 2022, reserves on the balance sheet associated with variable consideration were million. ​
Warrants	Warrants The Company accounts for its warrants to purchase common stock in accordance with ASC 480, Distinguishing Liabilities from Equity . In connection with entering into a senior secured term loan facility in February 2020, the Company issued warrants to purchase 35,000 shares of its common stock. In connection with an amendment to that facility in February 2021, the Company issued a warrant to purchase 11,250 shares of the Company’s common stock. These warrant instruments qualify for equity classification and have been allocated based upon the relative fair value of the base instrument and the warrant. These warrants are subject to repricing in the event of an offering of securities at a price lower than the existing strike price before December 31, 2022. See Note 7 for additional information. In connection with an underwritten public offering completed in October 2021, the Company issued warrants to purchase 333,333 shares of its common stock. This offering also triggered an adjustment to the exercise price of the existing warrants mentioned above, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. S In connection with a registered direct offering completed in March 2022, the Company issued warrants to purchase 1,242,813 shares of its common stock. This offering also triggered an adjustment to the exercise price of the existing warrants mentioned above, which resulted in a reduction of the strike price for these warrants. This reduction resulted in an immaterial increase to additional paid-in-capital. S In connection with a letter agreement and waiver entered into with an investor on April 2022, the Company issued warrants to purchase 212,188 shares of common stock, subject to adjustment thereunder. See Note 8 for additional information. In connection with a public offering completed in July 2022, the Company issued warrants to purchase 54,666,665 shares of its common stock. See Note 11 for additional information. This offering also triggered an adjustment to the exercise price of the existing warrants in connection with the senior secured term loan facility mentioned above, which resulted in a reduction of the strike price for these warrants.
Income Taxes	Income Taxes ​ The Company accounts for deferred taxes using the asset and liability method as specified by ASC 740, Income Taxes The Company has adopted the authoritative guidance on accounting for and disclosure of uncertainty in tax positions which prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The Company has no uncertain tax positions as of June 30, 2022 that qualify for either recognition or disclosure in the financial statements under this guidance.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation . The Company grants stock options for a fixed number of shares to employees and non-employees with an exercise price equal to no less than the fair value of the shares at grant date. Compensation cost is recognized for all share-based payments granted and is based on the grant-date fair value estimated using the weighted-average assumption of the Black-Scholes option pricing model based on key assumptions such as stock price, expected volatility and expected term. The Company elects to account for forfeitures when they occur. The equity instrument is not considered to be issued until the instrument vests. As a result, compensation cost is recognized over the requisite service period with an offsetting credit to additional paid-in capital. The Company also awards restricted stock units (“RSUs”) to employees and its board of directors. RSUs are generally subject to forfeiture if employment terminates prior to the completion of the vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of dilutive potential common shares outstanding during the period determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, common stock warrants, unvested RSUs and stock options are considered to be potentially dilutive securities but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive, and therefore, basic and diluted net loss per share were the same for all periods presented. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for both the three and six months ended June 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 2021 Common stock warrants 1,834,584 46,250 ​ Unvested restricted stock units 7,125 6,342 ​ Common stock options ​ 288,944 ​ 258,808 ​ Total 2,130,653 311,400 ​ ​
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation— Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815- 40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”). The guidance is effective for the Company on January 1, 2022. The adoption of this standard did not have a material impact on its financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Significant Accounting Policies
Schedule of outstanding potentially dilutive securities excluded from calculation of diluted net loss per share	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share for both the three and six months ended June 30, 2022 and 2021, respectively, because to do so would be anti-dilutive (in common equivalent shares): ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 2021 Common stock warrants 1,834,584 46,250 ​ Unvested restricted stock units 7,125 6,342 ​ Common stock options ​ 288,944 ​ 258,808 ​ Total 2,130,653 311,400 ​

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Measurements
Schedule of financial instruments measured at fair value by level within the fair value hierarchy	The following table sets forth the Company’s financial instruments measured at fair value by level within the fair value hierarchy as of June 30, 2022 and December 31, 2021 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 13,027 ​ $ — ​ $ — Total assets at fair value ​ $ 13,027 ​ $ — ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Level 1 Level 2 Level 3 December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ Cash and cash equivalents ​ $ 19,143 ​ $ — ​ $ — Total assets at fair value ​ $ 19,143 ​ $ — ​ $ —

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Prepaid Expenses and Other Current Assets
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2022 2021 Prepaid insurance ​ $ 199 ​ $ 775 ​ Other ​ 817 ​ 1,508 ​ Total prepaid expenses and other current assets ​ $ 1,016 ​ $ 2,283 ​

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Accrued Liabilities
Schedule of accrued liabilities	Accrued liabilities consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2022 2021 Accrued compensation ​ $ 1,545 ​ $ 2,086 ​ Accrued professional fees and other ​ 2,332 ​ 1,477 ​ Total accrued liabilities ​ $ 3,877 ​ $ 3,563 ​

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2022
Leases
Maturity of lease liabilities	Future minimum lease payments under non-cancellable leases as of June 30, 2022 were as follows (in thousands): ​ ​ ​ ​ ​ 2022 ​ $ 132 2023 ​ ​ 390 2024 ​ ​ 398 2025 ​ 101 Total ​ $ 1,021 Less: Interest ​ (152) Present value of lease liability ​ $ 869

Credit Agreement and Guaranty (

Credit Agreement and Guaranty (Tables)	6 Months Ended
	Jun. 30, 2022
Credit Agreement and Guaranty
Schedule of carrying amount of term loan	The fair value of the warrants as well as the debt issue costs incurred in connection with the entry into the Perceptive Credit Agreement, including a facility fee of 1% of the total amount of loans available under the facility, are presented as a direct deduction from the carrying amount of the term loan on the consolidated balance sheet as detailed below (in thousands). ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2022 ​ 2021 Notes payable $ 15,000 ​ $ 20,000 Debt issuance costs ​ ​ (412) ​ ​ (550) Warrant discount ​ ​ (1,958) ​ ​ (2,617) Total debt ​ $ 12,630 ​ $ 16,833 Less, current portion ​ ​ 12,630 ​ ​ 16,833 Long-term debt, less current portion ​ $ — ​ $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity
Schedule of allocation of stock-based compensation expense	Stock-based compensation expense was allocated as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ ​ June 30, ​ June 30, ​ ​ 2022 2021 ​ 2022 2021 Cost of goods sold ​ $ 31 ​ $ 75 ​ $ 75 ​ $ 135 ​ Research and development ​ ​ 91 ​ ​ 121 ​ ​ 194 ​ ​ 228 ​ Selling and marketing ​ ​ 40 ​ ​ 43 ​ ​ 80 ​ ​ 78 ​ General and administrative ​ 507 ​ 604 ​ 1,084 ​ 1,144 ​ Total ​ $ 669 ​ $ 843 ​ $ 1,433 ​ $ 1,585 ​

Organization and Description _2

Organization and Description of Business (Details) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 06, 2022	Jul. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Oct. 31, 2021
Nature of Operations
Accumulated deficit			$ 411,105,000		$ 411,105,000		$ 387,117,000
Cash, cash equivalents and marketable securities			$ 13,000,000		13,000,000
Working capital deficit					$ 10,300,000
Common stock that can be purchased with warrants (in shares)			1,242,813		1,242,813			333,333
General and Administrative Expense			$ 3,026,000	$ 3,852,000	$ 7,023,000	$ 7,653,000
Revision of Prior Period, Error Correction, Adjustment [Member]
Nature of Operations
General and Administrative Expense				$ (263,000)		$ (363,000)
Subsequent Event | Series B Pre-funded Warrants
Nature of Operations
Common stock that can be purchased with warrants (in shares)	7,518,334
Public offering
Nature of Operations
Proceeds from issuance of common stock and warrants	$ 22,200,000
Issuance of common stock (in shares)	19,148,332	7,518,334
Common stock that can be purchased with warrants (in shares)	7,518,334	38,296,664						333,333
Public offering | Series B Pre-funded Warrants
Nature of Operations
Warrant shares issued	7,518,334

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Advertising Costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Summary of Significant Accounting Policies
Advertising costs	$ 1.9	$ 3	$ 5.2	$ 6.1

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Deferred Financing Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Deferred Financing Costs
Facility fee percentage			1%
Interest expense [Member]
Deferred Financing Costs
Amortization of deferred financing costs	$ 66	$ 69	$ 139	$ 139

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) customer	Jun. 30, 2021 USD ($)
Concentration of risk, financial assets
Financial instruments with off-balance sheet risk of accounting loss, assets	$ 0		$ 0
Concentration risk, financial liabilities
Financial instruments with off-balance sheet risk of accounting loss, liabilities	0		0
Total revenue	$ 2,126	$ 1,185	$ 3,887	$ 1,301
Customer Concentration Risk | Sales Revenue
Concentration risk, financial liabilities
Number of major customers | customer			3
Customer Concentration Risk | Sales Revenue | Customer One
Concentration risk, financial liabilities
Total revenue			$ 700
Customer Concentration Risk | Sales Revenue | Customer Two
Concentration risk, financial liabilities
Total revenue			600
Customer Concentration Risk | Sales Revenue | Customer Three
Concentration risk, financial liabilities
Total revenue			$ 600
Customer Concentration Risk | Sales Revenue | Three Customers
Concentration risk, financial liabilities
Concentration risk, percentage			88%
Customer Concentration Risk | Accounts Receivable
Concentration risk, financial liabilities
Number of major customers | customer			3
Customer Concentration Risk | Accounts Receivable | Customer One
Concentration risk, financial liabilities
Concentration risk, percentage			40%
Customer Concentration Risk | Accounts Receivable | Customer Two
Concentration risk, financial liabilities
Concentration risk, percentage			22%
Customer Concentration Risk | Accounts Receivable | Customer Three
Concentration risk, financial liabilities
Concentration risk, percentage			31%

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Co-Payment Assistance (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Receivables [Abstract]
Provision for revenue reserve	$ 1,600	$ 345	$ 2,800	$ 349
Reserve for variable consideration	$ 1,900		$ 1,900

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Warrants (Details) - shares	Jul. 31, 2022	Jul. 06, 2022	Jun. 30, 2022	Apr. 30, 2022	Oct. 31, 2021	Feb. 28, 2021	Feb. 29, 2020
Warrants
Common stock that can be purchased with warrants (in shares)				212,188		11,250
Common stock that can be purchased with warrants (in shares)			1,242,813		333,333
Public offering
Warrants
Common stock that can be purchased with warrants (in shares)	38,296,664	7,518,334			333,333
Subsequent Event | Public offering
Warrants
Common stock that can be purchased with warrants (in shares)	54,666,665
Common stock warrants
Warrants
Common stock that can be purchased with warrants (in shares)							35,000
Warrants | Public offering
Warrants
Common stock that can be purchased with warrants (in shares)	15,036,668

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Income Taxes (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Uncertainty in tax positions
Uncertain tax positions	$ 0

Summary of Significant Accou_10

Summary of Significant Accounting Policies - Net Loss Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	2,130,653	311,400
Common stock warrants
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	1,834,584	46,250
Unvested restricted stock units
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	7,125	6,342
Common stock options
Anti-dilutive securities
Anti-dilutive securities excluded from the calculation of diluted net loss per share (in shares)	288,944	258,808

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured at Fair Value by Hierarchy Level (Details) - Recurring - Level 1 - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets:
Cash and cash equivalents	$ 13,027	$ 19,143
Total assets at fair value	$ 13,027	$ 19,143

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets
Prepaid insurance	$ 199	$ 775
Other	817	1,508
Total prepaid expenses and other current assets	$ 1,016	$ 2,283

Accrued Liabilities (Details)

Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accrued Liabilities
Accrued compensation	$ 1,545	$ 2,086
Accrued professional fees and other	2,332	1,477
Total accrued liabilities	$ 3,877	$ 3,563

Leases - Summary (Details)

Leases - Summary (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) lease	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) lease	Jun. 30, 2021 USD ($)
Leases
Number of finance leases | lease	0		0
Number of operating leases | lease	1		1
Lessee, Operating Lease, Existence of Option to Extend [true false]			true
Renewal term	5 years		5 years
Operating lease expense | $	$ 89,000	$ 38,000	$ 182,000	$ 76,000
Operating lease expense information:
Cash paid for amounts included in measurement of lease liabilities | $	$ 69,000	$ 34,000	$ 90,000	$ 66,000
Weighted-average remaining lease term (years)	2 years 9 months		2 years 9 months
Weighted-average discount rate	11.80%		11.80%

Leases - Maturity of lease liab

Leases - Maturity of lease liabilities (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Operating Leases
2022	$ 132
2023	390
2024	398
2025	101
Total	1,021
Less: Interest	(152)
Present value of lease liability	$ 869

Credit Agreement and Guaranty_2

Credit Agreement and Guaranty (Details)

3 Months Ended

6 Months Ended

Jul. 25, 2022 USD ($)

Jul. 08, 2022 USD ($)

Jan. 07, 2022 USD ($)

Feb. 26, 2021 USD ($) $ / shares shares

Feb. 10, 2020 USD ($) item Y $ / shares

Dec. 31, 2023 USD ($)

Jun. 30, 2022 USD ($) $ / shares shares

Jul. 31, 2022 $ / shares shares

Mar. 31, 2022 $ / shares shares

Feb. 28, 2022 $ / shares

Oct. 31, 2021 $ / shares shares

Sep. 30, 2021 $ / shares

Debt Instrument [Line Items]

Repayments of debt

$ 5,000,000

Interest rate (as a percent)

11.75%

11.75%

Percentage of annual interest rate

3%

Common stock that can be purchased with warrants (in shares) | shares

1,242,813

333,333

Proceeds from warrant exercises

$ 20,000,000

Facility fee percentage

1%

Perceptive Credit Agreement

Debt Instrument [Line Items]

Repayments of debt

$ 5,000,000

$ 5,000,000

Debt instrument, prepayment premium due

$ 0

$ 0

Minimum cash covenants

$ 3,000,000

Revenue generated under debt

$ 87,100,000

$ 53,000,000

Perceptive Credit Agreement | Perceptive Warrants

Debt Instrument [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 114.80

Common stock that can be purchased with warrants (in shares) | shares

11,250

35,000

Number of warrants issued | item

2

Beneficial ownership percentage

19.99%

Facility fee percentage

1%

Perceptive Credit Agreement | First Seven Lakhs Shares

Debt Instrument [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 149.60

$ 105.52

$ 14.90

$ 105.52

$ 141.60

$ 141.60

$ 186.80

Common stock that can be purchased with warrants (in shares) | shares

17,500

17,500

17,500

17,500

Perceptive Credit Agreement | Remaining Seven Lakhs Shares

Debt Instrument [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 186.80

$ 86.61

$ 12.37

$ 86.61

115.20

$ 115.20

149.60

Common stock that can be purchased with warrants (in shares) | shares

17,500

17,500

17,500

17,500

Perceptive Credit Agreement | Warrants

Debt Instrument [Line Items]

Exercise price of warrants (in dollars per share) | $ / shares

$ 69.13

$ 10.03

$ 69.13

$ 90.80

$ 90.80

$ 114.80

Common stock that can be purchased with warrants (in shares) | shares

11,250

11,250

11,250

Senior secured delayed draw term loan facility | Perceptive Credit Agreement

Debt Instrument [Line Items]

Maximum borrowing capacity

$ 35,000,000

Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche One

Debt Instrument [Line Items]

Amount borrowed

5,000,000

Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche Two

Debt Instrument [Line Items]

Amount borrowed

15,000,000

Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche Three

Debt Instrument [Line Items]

Amount borrowed

$ 15,000,000

Senior secured delayed draw term loan facility | Perceptive Credit Agreement, Tranche Four

Debt Instrument [Line Items]

Amount borrowed

$ 10,000,000

Subsequent Event | Perceptive Credit Agreement

Debt Instrument [Line Items]

Prepayment of outstanding principal

$ 7,000,000

Monthly principal payments

$ 75,000

LIBOR | Perceptive Credit Agreement

Debt Instrument [Line Items]

Variable interest rate margin (as a percent)

10.25%

Interest rate for the base rate

1.50%

Prepayment Occur on or Before February, 10, 2022 | Perceptive Credit Agreement

Debt Instrument [Line Items]

Prepayment premium percentage

4%

Prepayment Occur on or Before February, 10, 2023 | Perceptive Credit Agreement

Debt Instrument [Line Items]

Prepayment premium percentage

2%

Two Thousand Twenty Perceptive Warrants [Member]

Debt Instrument [Line Items]

Fair value of warrants

$ 3,600,000

Two Thousand Twenty One Perceptive Warrants [Member]

Debt Instrument [Line Items]

Fair value of warrants

$ 1,100,000

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants

Debt Instrument [Line Items]

Warrants and rights outstanding, term

7 years

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants | Volatility

Debt Instrument [Line Items]

Warrants, Measurement Input | item

0.700

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants | Risk free interest rate

Debt Instrument [Line Items]

Warrants, Measurement Input | item

0.0147

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants | Expected life

Debt Instrument [Line Items]

Warrants, Measurement Input | Y

7

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Perceptive Warrants | Fair value

Debt Instrument [Line Items]

Warrants, Measurement Input | item

160.40

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Maximum | Perceptive Warrants | Strike price

Debt Instrument [Line Items]

Warrants, Measurement Input | item

186.80

Option pricing model | Two Thousand Twenty Perceptive Warrants [Member] | Minimum | Perceptive Warrants | Strike price

Debt Instrument [Line Items]

Warrants, Measurement Input | item

149.60

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Warrants | Volatility

Debt Instrument [Line Items]

Warrants, Measurement Input | item

1.035

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Warrants | Risk free interest rate

Debt Instrument [Line Items]

Warrants, Measurement Input | item

0.0115

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Warrants | Strike price

Debt Instrument [Line Items]

Warrants, Measurement Input | item

114.80

Option pricing model | Two Thousand Twenty One Perceptive Warrants [Member] | Perceptive Credit Agreement | Expected life

Debt Instrument [Line Items]

Warrants, Measurement Input | Y

7

Warrants and rights outstanding, term

7 years

Credit Agreement and Guaranty -

Credit Agreement and Guaranty - Carrying Amount Of term Loan (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Credit Agreement and Guaranty
Notes payable	$ 15,000,000		$ 15,000,000		$ 20,000,000
Debt issuance costs	(412,000)		(412,000)		(550,000)
Warrant discount	(1,958,000)		(1,958,000)		(2,617,000)
Total	12,630,000		12,630,000		16,833,000
Less, current portion	12,630,000		12,630,000		$ 16,833,000
Warrants and debt issue costs	$ 378,000	$ 398,000	$ 797,000	$ 734,000

Stockholders' Equity - Amended

Stockholders' Equity - Amended and Restated Certificate of Incorporation (Details) - shares	Jun. 30, 2022	Jan. 07, 2022	Jan. 06, 2022	Dec. 31, 2021
Stockholders' Equity
Common stock, authorized (in shares)	300,000,000	300,000,000	150,000,000	300,000,000

Stockholders' Equity - Common S

Stockholders' Equity - Common Stock (Details) $ / shares in Units, $ in Millions

1 Months Ended

2 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jul. 06, 2022 $ / shares shares

Apr. 27, 2022 shares

Apr. 25, 2022 $ / shares shares

Apr. 04, 2022 shares

Mar. 15, 2022 shares

Mar. 14, 2022 USD ($) $ / shares shares

Jan. 10, 2022 USD ($)

Mar. 15, 2021 shares

Oct. 31, 2022 shares

Jul. 31, 2022 USD ($) $ / shares shares

Apr. 30, 2022 shares

Oct. 31, 2021 USD ($) $ / shares shares

Mar. 31, 2021 USD ($) shares

Jun. 30, 2022 USD ($) $ / shares shares

Jun. 30, 2022 $ / shares shares

Mar. 31, 2022 $ / shares shares

Jun. 30, 2021 shares

Mar. 31, 2021 USD ($) shares

Jun. 30, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($) $ / shares

Feb. 28, 2022 $ / shares

Sep. 30, 2021 $ / shares

Feb. 26, 2021 $ / shares shares

Oct. 02, 2020 USD ($)

Feb. 10, 2020 $ / shares

Sale of stock

Fractional Shares Issued Upon Reverse Stock Split

0

Common stock that can be purchased with warrants (in shares)

333,333

1,242,813

1,242,813

1,242,813

Stock stated value | $ / shares

$ 0.0001

$ 0.0001

$ 0.0001

$ 0.0001

Common stock

Sale of stock

Conversion of convertible preferred stock (in shares)

303,125

Common stock | Subsequent Event

Sale of stock

Issuance of common stock (in shares)

19,148,332

Perceptive Warrants | Perceptive Credit Agreement

Sale of stock

Common stock that can be purchased with warrants (in shares)

35,000

35,000

35,000

11,250

Exercise price of warrants (in dollars per share) | $ / shares

$ 114.80

First Seven Lakhs Shares | Perceptive Credit Agreement

Sale of stock

Common stock that can be purchased with warrants (in shares)

17,500

17,500

17,500

17,500

17,500

17,500

Exercise price of warrants (in dollars per share) | $ / shares

$ 14.90

$ 141.60

$ 105.52

$ 105.52

$ 105.52

$ 105.52

$ 141.60

$ 186.80

$ 149.60

Remaining Seven Lakhs Shares | Perceptive Credit Agreement

Sale of stock

Common stock that can be purchased with warrants (in shares)

17,500

17,500

17,500

17,500

17,500

17,500

Exercise price of warrants (in dollars per share) | $ / shares

$ 12.37

$ 115.20

$ 86.61

$ 86.61

$ 86.61

$ 86.61

115.20

149.60

$ 186.80

Warrants | Perceptive Credit Agreement

Sale of stock

Common stock that can be purchased with warrants (in shares)

11,250

11,250

11,250

Exercise price of warrants (in dollars per share) | $ / shares

$ 10.03

$ 90.80

$ 69.13

$ 69.13

$ 69.13

$ 69.13

$ 90.80

$ 114.80

Series A Warrants | Subsequent Event

Sale of stock

Exercise price of warrants (in dollars per share) | $ / shares

$ 0.90

2020 Shelf Registration Statement

Sale of stock

Aggregate amount of securities issuable | $

$ 200

2022 Preferred Stock Offering

Sale of stock

Common stock that can be purchased with warrants (in shares)

30,313

Proceeds from issuance of common stock in public offering, net of offering costs | $

$ 4.1

Fair Value Of Warrants | $

$ 2.1

Exercise price of warrants (in dollars per share) | $ / shares

$ 10

Conversion price | $ / shares

$ 8

Preferred Stock, convertible, shares issuable

606,250

Exercisable term

6 months

Stock stated value | $ / shares

$ 1,000

Warrants and rights outstanding, term

5 years

Duration From Offering To Anniversary Of Closing

180 days

2022 Preferred Stock Offering | Strike price

Sale of stock

Warrants, Measurement Input

10.40

2022 Preferred Stock Offering | Fair value

Sale of stock

Warrants, Measurement Input

9.48

2022 Preferred Stock Offering | Series A Warrants

Sale of stock

Common stock that can be purchased with warrants (in shares)

212,188

606,250

Exercise price of warrants (in dollars per share) | $ / shares

$ 10.40

$ 10.40

Exercisable term

6 months

Warrants and rights outstanding, term

5 years

Warrant Exercisable Term

5 years

2022 Preferred Stock Offering | Series A Warrants | Volatility

Sale of stock

Warrants, Measurement Input

1.119

2022 Preferred Stock Offering | Series A Warrants | Risk free interest rate

Sale of stock

Warrants, Measurement Input

0.021

2022 Preferred Stock Offering | Series A Warrants | Expected life

Sale of stock

Warrants, Measurement Input

5.5

2022 Preferred Stock Offering | Series B Warrants

Sale of stock

Common stock that can be purchased with warrants (in shares)

606,250

Exercise price of warrants (in dollars per share) | $ / shares

$ 10.40

Exercisable term

6 months

Warrants and rights outstanding, term

1 year 6 months

2022 Preferred Stock Offering | Series B Warrants | Volatility

Sale of stock

Warrants, Measurement Input

0.697

2022 Preferred Stock Offering | Series B Warrants | Risk free interest rate

Sale of stock

Warrants, Measurement Input

0.016

2022 Preferred Stock Offering | Series B Warrants | Expected life

Sale of stock

Warrants, Measurement Input

1.5

At-the-market sales | Common stock

Sale of stock

Issuance of common stock (in shares)

172,879

8,687,502

25,623

114,826

13,023

Proceeds from issuance of common stock in public offering, net of offering costs | $

$ 9.3

At-the-market sales | Common stock | Maximum

Sale of stock

Commission percentage

3%

Authorized value for shares issuance | $

$ 50

$ 50

Public offering

Sale of stock

Issuance of common stock (in shares)

19,148,332

7,518,334

Common stock that can be purchased with warrants (in shares)

7,518,334

38,296,664

333,333

Share price (in dollars per share) | $ / shares

$ 0.90

Public offering | Common stock

Sale of stock

Issuance of common stock (in shares)

666,666

19,148,332

Common stock that can be purchased with one-half of warrant (in shares)

1

Share price (in dollars per share) | $ / shares

$ 0.8999

$ 34

Proceeds from issuance of common stock in public offering, net of offering costs | $

$ 22.2

$ 21.1

Public offering | Warrants

Sale of stock

Common stock that can be purchased with warrants (in shares)

15,036,668

Public offering | Pre-funded warrants

Sale of stock

Common stock that can be purchased with warrants (in shares)

7,518,334

2022 ATM

Sale of stock

Issuance of common stock (in shares)

8,687,502

Proceeds from issuance of common stock in public offering, net of offering costs | $

$ 12.2

2022 ATM | Common stock

Sale of stock

Issuance of common stock (in shares)

25,623

Proceeds from issuance of common stock in public offering, net of offering costs | $

$ 0.3

2022 ATM | Common stock | Maximum

Sale of stock

Commission percentage

3%

Authorized value for shares issuance | $

$ 50

2022 ATM | New Warrant [Member]

Sale of stock

Warrant Exercisable Term

6 months

H.C. Wainwright & Co., LLC, Sales Agent [Member]

Sale of stock

Commission percentage

3%

H.C. Wainwright & Co., LLC, Sales Agent [Member] | Common stock

Sale of stock

Issuance of common stock (in shares)

12,841,000

Series A Preferred Stock

Sale of stock

Conversion of stock shares converted

2,425

Series A Preferred Stock | 2022 Preferred Stock Offering

Sale of stock

Issuance of common stock (in shares)

2,425

Series B Preferred Stock

Sale of stock

Issuance of common stock (in shares)

2,425

Conversion of stock shares converted

303,125

Series B Preferred Stock | 2022 Preferred Stock Offering

Sale of stock

Issuance of common stock (in shares)

2,425

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock-Based Compensation Expense
Total stock-based compensation expense	$ 669	$ 843	$ 1,433	$ 1,585
Cost of goods sold
Stock-Based Compensation Expense
Total stock-based compensation expense	31	75	75	135
Research and development
Stock-Based Compensation Expense
Total stock-based compensation expense	91	121	194	228
Selling and marketing
Stock-Based Compensation Expense
Total stock-based compensation expense	40	43	80	78
General and administrative
Stock-Based Compensation Expense
Total stock-based compensation expense	$ 507	$ 604	$ 1,084	$ 1,144

Income Taxes - Sale of New Jers

Income Taxes - Sale of New Jersey Net Operating Losses (Details) - USD ($) $ in Millions	1 Months Ended
	Apr. 30, 2022	Jan. 31, 2021	Jan. 31, 2018
Sale of New Jersey Net Operating Losses
Additional cash benefit received	$ 4.7
Sale of unused NOLs | New Jersey
Sale of New Jersey Net Operating Losses
Maximum lifetime benefit under the Program		$ 20	$ 15
Sale of unused NOLs | New Jersey | Minimum
Sale of New Jersey Net Operating Losses
Allowable sale of unused tax benefits as a percentage of total value			80%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Apr. 30, 2020	Jun. 30, 2022
Commitments and Contingencies
Future purchase commitments		$ 239.5
Corium Agreement [Member]
Commitments and Contingencies
Quarterly minimum volume amount of product to be ordered	$ 5.6
Additional fee payable as a percentage of transfer price for units ordered	25%
Percentage of additional fee as penalty percent		25%

Subsequent Event (Details)

Subsequent Event (Details) - USD ($)	Jul. 25, 2022	Jul. 06, 2022	Jun. 30, 2022	Oct. 31, 2021
Subsequent Event
Common stock that can be purchased with warrants (in shares)			1,242,813	333,333
Subsequent event | Corium Agreement [Member]
Subsequent Event
2022	$ 5,300,000
2023	7,000,000
2024	22,500,000
Subsequent event | Perceptive Credit Agreement
Subsequent Event
Prepayment of outstanding principal	7,000,000
Monthly principal payments	$ 75,000
Subsequent event | Common stock
Subsequent Event
Issuance of common stock (in shares)		19,148,332
Subsequent event | Series A Warrants
Subsequent Event
Exercise price of warrants (in dollars per share)		$ 0.90
Subsequent event | Series A-1 warrants
Subsequent Event
Warrant Exercisable Term		5 years
Subsequent event | Series A-2 warrants
Subsequent Event
Warrant Exercisable Term		13 months
Subsequent event | Series B Pre-funded Warrants
Subsequent Event
Common stock that can be purchased with warrants (in shares)		7,518,334
Warrant Shares Issued		$ 7,518,334
Subsequent event | Offering
Subsequent Event
Proceeds from issuance of common stock, net of offering costs		$ 22,200,000
Subsequent event | Offering | Series A-1 warrants
Subsequent Event
Issuance of common stock (in shares)		26,666,666
Subsequent event | Offering | Series A-2 warrants
Subsequent Event
Issuance of common stock (in shares)		26,666,666
Subsequent event | Placement Agent
Subsequent Event
Common stock that can be purchased with warrants (in shares)		1,333,333
Exercise price of warrants (in dollars per share)		$ 1.125
Commission Percentage on Stock Offering		7%